Innohep

Tinzaparin sodium, the active ingredient in Innohep, is a low molecular weight heparin presented as a sterile solution for subcutaneous use. It is employed to prevent and treat venous thromboembolic disorders such as deep vein thrombosis and pulmonary embolism in adult patients undergoing surgery or with acute coronary syndrome.

GNH USA supplies Innohep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Innohep (tinzaparin sodium) is used in the management of venous thromboembolism and related cardiovascular conditions.

- Deep vein thrombosis (post‑operative): prevents clot formation and extension in patients after major surgery. - Acute deep vein thrombosis: treats existing clots by enhancing natural anticoagulation. - Pulmonary embolism: both prevents new emboli and aids in the treatment of established emboli. - Acute coronary syndrome: reduces the risk of thrombotic complications during and after the event.

Tinzaparin sodium may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the subcutaneous injection site. - Bruising or hematoma: localized bleeding under the skin. - Minor bleeding: such as epistaxis or gum bleeding.

Serious or Rare Side Effects: - Major hemorrhage: life‑threatening bleeding in internal organs or the central nervous system. - Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet decline that can paradoxically cause clotting. - Spinal or epidural hematoma: bleeding in the spinal canal, especially after neuraxial anesthesia. - Severe allergic reaction: anaphylaxis or serum sickness‑like symptoms.

When using Innohep, several safety considerations should be observed to minimize risks. - Renal impairment: assess kidney function and adjust dose or monitor anti‑Xa levels. - History of heparin‑induced thrombocytopenia: avoid use due to risk of recurrence. - Concurrent anticoagulants: increased bleeding risk when combined with warfarin, direct oral anticoagulants, or thrombolytics. - Invasive procedures: discontinue before surgery or epidural catheter placement to reduce bleeding complications. - Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Tinzaparin sodium can interact with other medicines, altering its anticoagulant effect or increasing bleeding risk.

Major Interactions (Avoid): - Other anticoagulants (e.g., warfarin, direct thrombin inhibitors): additive anticoagulation may cause severe bleeding. - Thrombolytic agents (e.g., alteplase): combined use markedly raises hemorrhage risk. - Neuraxial anesthesia or spinal puncture: concurrent use can precipitate spinal hematoma.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may enhance mucosal bleeding. - Antiplatelet agents (e.g., clopidogrel, aspirin): increase overall bleeding tendency.